Replies to post #109276 on Regen BioPharma Inc (RGBP)

[StocktonCA]

Eli Lilly Merger/Acquisition Explained!

# 1 (24+) Patents worth $$ BILLIONS

https://patents.google.com/?inventor=David+Koos&sort=new
https://patents.justia.com/assignee/regen-biopharma-inc
https://www.otcmarkets.com/filing/html?id=15088630&guid=dk3wkKwg3iFaJth

# 2 Eli Lilly had prior collaborative arrangement with RGBP with joint I.P. claim on NR2F6 for developing an mRNA Cancer Vaccine

https://www.biospace.com/article/releases/regen-biopharma-enters-into-open-innovation-drug-discovery-program-agreement-with-eli-lilly-/

# 3 Eli Lilly-Curevac 2017 Partnership to develop mRNA Cancer Vaccine FAILED Ending June 2020 due to Curevac's faulty research data. Lilly lost $100 Million in shared development costs. Merger/Acquisition is the shortest path to get back on track!

# 4 Licensing of (1) Patent with (2) INDs (New Drug Applications) for treating pancreatic & colon cancer by mRNA Vaccine; The Future of Medicine

https://www.aamc.org/news-insights/mrna-technology-promises-revolutionize-future-vaccines-and-treatments-cancer-infectious-diseases

# 5 On track with Big Pharmas developing mRNA Cancer Vaccines; a TRILLION Dollar Market

https://www.ventureradar.com/keyword/Cancer%20Vaccines

# 6 FDA Patent Approval

https://newsinvasion24.com/regen-biopharma-inc-otcmkts-rgbp-gets-approval-for-cancer-vaccine-patent/

# 7 Partnership:Oncology Pharma Paid $1M for Patent Licensing; will now Post Quarterly Revenues for 15 Years

# 8 Certification Audit of RGBP by BRG completed 11/15/21. This is indicative of an Industry Standard Merger/Acquisition

#9 On 4/27/21 CEO files Acquisition Intent with 8K

https://www.otcmarkets.com/filing/conv_pdf?id=14894907&guid=55ywkew26hwfJth

Opinion ONLY! All Feedback welcome

Be well and prosper...

[29YEARINVESTOR]

15 Mar 2022 Preclinical trials in Myelodysplastic syndromes in USA (IV) (Regen Biopharma pipeline)
10 Mar 2022 Preclinical development in Breast cancer and Myelodysplastic syndrome is ongoing USA

https://adisinsight.springer.com/drugs/800037634

RGBP waiting on fast track acceptance.
https://www.prnewswire.com/news-releases/regen-biopharma-inc-announces-program-to-fast-track-its-checkpoint-inhibitor-program-utilizing-modified-mrna-and-sirna-technologies-301499817.html